You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ)與藍鵲生物共同開展流感病毒mRNA疫苗產品開發及商業化合作
格隆匯 08-27 21:56

格隆匯8月27日丨沃森生物(300142.SZ)公佈,2021年8月26日,公司第四屆董事會第二十七次會議審議通過了《關於公司簽署流感病毒mRNA疫苗產品開發及商業化合作協議的議案》,董事會同意公司與上海藍鵲生物醫藥有限公司(簡稱“藍鵲生物”)簽署《流感病毒mRNA疫苗產品開發及商業化合作協議》,共同開展流感病毒mRNA疫苗的產品開發及商業化合作。

藍鵲生物在mRNA藥物研發領域具有核心優勢,自創建以來一直聚焦mRNA藥物研發,擁有抗原設計、mRNA序列深度優化、mRNA全流程工藝和檢測方法、成熟的LNP包封工藝,並在mRNA藥物關鍵原輔料如修飾核苷酸、帽子類似物、酶、陽離子脂質上具有自主研發能力。公司通過與藍鵲生物合作進行新型mRNA疫苗開發,可進一步拓展公司研發產品線,有利於公司的長遠發展。

公司表示,簽署該協議將有利於保障目標藥物的研發和後期商業化,充分利用雙方各自擁有的研發、註冊、臨牀、產業化和國際營銷方面豐富的經驗和專業能力,建立戰略合作聯盟,採取多種方式,共同進行新產品的臨牀前、臨牀開發和產業化工作,是綜合考慮了公司整體經營發展規劃而做出的謹慎決策,符合公司的整體發展戰略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account